A Phase 4 interventional study of pitavastatin and pravastatin in Primary Dyslipidemia and Mixed Dyslipidemia, sponsored by Kowa Research Institute, Inc.. Completed at 44 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-05-08.
Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pitavastatin in Dyslipidemias — 2 open to participants now, 3 under way, none of them phase 3. pitavastatin · Dyslipidemias.
Among the 21 studies testing pitavastatin in Dyslipidemias, this one is the 10th largest by enrollment, is one of 2 that started in 2010, is one of 6 in phase 4, and was the 10th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →2 of the 21 studies testing pitavastatin in Dyslipidemias are open now, in 2 countries. Recruiting first, the newest first:
Eccogene · Sites in Australia
Ages 18–65 · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
By country, each count listing its studies:
pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2010.
This study's enrollment of 328 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 252 across the 21 interventional studies. Of the 13 that completed or were terminated, 12 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Institute, Inc., one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.
20 studies in Dyslipidemias by Kowa Company, Ltd.: none open now, none under way, none of them phase 3. Of 18 finished, 13 (72%) have results posted.
Among the 20 studies in Dyslipidemias by Kowa Company, Ltd., this one is the 10th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 4, and was the 10th registered.
Kowa Company, Ltd.’s Dyslipidemias studies by the year they started, since 2005.
1 of the studies testing pitavastatin in Dyslipidemias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07726368EccogeneStudy of ECC4703 With Sulfasalazine and Pitavastatin | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pitavastatin in Dyslipidemias, from their registry updates:
Among Kowa Company, Ltd.’s 20 in Dyslipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pitavastatin
Drug: pravastatin
pitavastatin 4 mg once daily (QD)
Also known as: Livalo
Pravastatin 40 mg once daily (QD)
Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12
Time frame: Baseline and 12 weeks
| Milestone | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) |
|---|---|---|
| Started | 164 | 164 |
| Completed | 158 | 157 |
| Not completed | 6 | 7 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Persistent alt or ast elevation | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Subject non-compliance | 0 | 1 |
| Withdrew: Ldl-c elevation exceeding 250 mg/dl | 0 | 1 |
| percent | Pitavastatin 4 mg Once Daily (QD) | Pravastatin 40 mg Once Daily (QD) |
|---|---|---|
| Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12 | -34.8 ± 1.20 | -22.7 ± 1.22 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 4 mg Once a Day (QD) | — | 2/164 (1.2%) | 19/164 (11.6%) |
| Pravastatin 40 mg Once a Day (QD) | — | 1/164 (0.6%) | 14/164 (8.5%) |
| Event | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) |
|---|---|---|
| appendicitis perforatedGastrointestinal disorders | 1/164 | 0/164 |
| prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/164 | 0/164 |
| lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/164 | 1/164 |
| Event | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) |
|---|---|---|
| NasopharyngitisInfections and infestations | 11/164 | 5/164 |
| upper respiratory tract infectionInfections and infestations | 8/164 | 9/164 |
| Age, Categorical(Participants) | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 122 | 127 | 249 |
| >=65 years | 42 | 37 | 79 |
| Age Continuous(years) | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) | Total |
|---|---|---|---|
| Mean | 58.8 ± 8.93 | 57.0 ± 10.23 | 57.9 ± 9.63 |
| Sex: Female, Male(Participants) | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) | Total |
|---|---|---|---|
| Female | 83 | 79 | 162 |
| Male | 81 | 85 | 166 |
| Region of Enrollment(participants) | Pitavastatin 4 mg Once a Day (QD) | Pravastatin 40 mg Once a Day (QD) | Total |
|---|---|---|---|
| United States | 164 | 164 | 328 |
The record gives a start of Oct 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin
Kowa Research Institute, Inc. →